Patents by Inventor Helen Francis-Lang

Helen Francis-Lang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SCDs as modifiers of the p53 pathway and methods of use
    Patent number: 8771942
    Abstract: Human SCD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SCD are provided.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: July 8, 2014
    Assignee: Exelixis, Inc.
    Inventors: Marcia Belvin, Helen Francis-Lang, Lori Friedman, Gregory D. Plowman, Timothy S. Heuer
  • PLKS as modifiers of the beta catenin pathway and methods of use
    Patent number: 8632962
    Abstract: Human PLK genes are identified as modulators of the beta catenin pathway, and thus are therapeutic targets for disorders associated with defective beta catenin function. Methods for identifying modulators of beta catenin, comprising screening for agents that modulate the activity of PLK are provided.
    Type: Grant
    Filed: November 23, 2004
    Date of Patent: January 21, 2014
    Assignee: Exelixis, Inc.
    Inventors: Helen Francis-Lang, Christopher G. Winter, Richard Benn Abegania Ventura, Lynn Margaret Bjerke, Timothy S. Heuer
  • RORS as modifiers of the p21 pathway and methods of use
    Patent number: 8426147
    Abstract: Human ROR genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of ROR are provided.
    Type: Grant
    Filed: December 1, 2008
    Date of Patent: April 23, 2013
    Assignee: Exelixis, Inc.
    Inventors: Helen Francis-Lang, Lori Friedman, Thomas Kidd, Siobhan Roche, Haiguang Zhang
  • MAP3Ks as modifiers of the p53 pathway and methods of use
    Patent number: 8268548
    Abstract: Human MAP3K genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MAP3K are provided.
    Type: Grant
    Filed: April 18, 2007
    Date of Patent: September 18, 2012
    Assignee: Exelixis, Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danix Li, Roel P. Funke
  • METHODS AND APPARATUS RELATED TO MANAGEMENT OF EXPERIMENTS
    Publication number: 20120215481
    Abstract: In one embodiment, a method includes sending an indicator of an availability of a sample from a sample pool stored in a physical inventory. The sample being included in the sample pool based on an attribute of the sample satisfying a condition associated with the sample pool. An indicator that the sample has been selected from the sample pool for analysis at a first test site included in an array of test sites is received. A rule is retrieved from a rule database based on an experimental parameter value associated with the first test site. At least one of the experimental parameter value associated with the first test site or an experimental parameter value associated with a second test site is modified based on a condition within the rule being satisfied.
    Type: Application
    Filed: February 17, 2012
    Publication date: August 23, 2012
    Applicant: Nodality, Inc.
    Inventors: Todd M. Covey, Darwin A. Farrow, Barton J. Friedland, Helen Francis-Lang, Malcolm Francis-Lang, Justin W. Mccarthy, Norman B. Purvis, JR., Santosh K. Putta, David B. Rosen, David M. Soper, David C. Spellmeyer
  • Marks as modifiers of the p53 pathway and methods of use
    Patent number: 8153384
    Abstract: Human MARK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MARK are provided.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: April 10, 2012
    Assignee: Exelixis, Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Helen Francis-Lang, Danxi Li, Roel P. Funke, Marcia Belvin, Mario N. Lioubin
  • HPRP4s modifiers of the p53 pathway and methods of use
    Patent number: 7993829
    Abstract: Human hPRP4 genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of hPRP4 are provided.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: August 9, 2011
    Assignee: Exelixis Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Tak Hung, Helen Francis-Lang, Danix Li, Roel P. Funke, Michael Costa
  • GFATS as Modifiers of the P53 Pathway and Methods of Use
    Publication number: 20110159508
    Abstract: Human GFAT genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of GFAT are provided.
    Type: Application
    Filed: October 7, 2010
    Publication date: June 30, 2011
    Applicant: EXELIXIS, INC.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke
  • C20ORF23 as modifier of the IGFR pathway and methods of use
    Patent number: 7943302
    Abstract: Human C20ORF23 genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of C20ORF23 are provided.
    Type: Grant
    Filed: March 10, 2005
    Date of Patent: May 17, 2011
    Assignee: Exelixis, Inc.
    Inventors: Lori Friedman, Helen Francis-Lang, Annette L. Parks, Kenneth James Shaw, Lynn Margaret Bjerke, Timothy S. Heuer
  • PAKs as Modifiers of the CHK Pathway and Methods of Use
    Publication number: 20110059066
    Abstract: Human PAK genes are identified as modulators of the CHK pathway, and thus are therapeutic targets for disorders associated with defective CHK function. Methods for identifying modulators of CHK, comprising screening for agents that modulate the activity of PAK are provided.
    Type: Application
    Filed: July 1, 2010
    Publication date: March 10, 2011
    Applicant: EXELIXIS, INC.
    Inventors: Helen Francis-Lang, Siobhan Roche, Lickteig Kim
  • PDEs as modifiers of the IGFR pathways and methods of use
    Patent number: 7888047
    Abstract: Human PDE genes are identified as modulators of the IGFR pathway and thus are therapeutic targets for disorders associated with defective IGFR function Methods for identifying modulators of IGFR comprising screening for agents that modulate the activity of PDE are provided.
    Type: Grant
    Filed: March 10, 2005
    Date of Patent: February 15, 2011
    Assignee: Exelixis, Inc.
    Inventors: Lori Friedman, Helen Francis-Lang, Annette L. Parks, Kenneth James Shaw, Lynn Margaret Bjerke, Timothy S. Heuer
  • P4HAS as modifiers of the IGFR pathway and methods of use
    Patent number: 7888048
    Abstract: Human P4HA genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of P4HA are provided.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: February 15, 2011
    Assignee: Exelixis, Inc.
    Inventors: Lori S. Friedman, Helen Francis-Lang, Annette L. Parks, Kenneth James Shaw, Timothy S. Heuer, Lynn Margaret Bjerke
  • Marks as modifiers of the p53 pathway and methods of use
    Publication number: 20100325743
    Abstract: Human MARK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MARK are provided.
    Type: Application
    Filed: June 10, 2010
    Publication date: December 23, 2010
    Applicant: Exelixis, Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke, Mario N. Lioubin
  • MAN2As as modifiers of the IGFR pathway and methods of use
    Patent number: 7785805
    Abstract: Human MAN2A genes are identified as modulators of the IGFR pathway and thus are therapeutic targets for disorders associated with defective IGFR function Methods for identifying modulators of IGFR comprising screening for agents that modulate the activity of MAN2A are provided.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: August 31, 2010
    Assignee: Exelixis, Inc.
    Inventors: Lori Friedman, Helen Francis-Lang, Annette L. Parks, Kenneth James Shaw, HaiGuang Zhang, Timothy S. Heuer
  • SCDs As Modifiers of the p53 Pathway and Methods of Use
    Publication number: 20100159470
    Abstract: Human SCD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SCD are provided.
    Type: Application
    Filed: February 26, 2010
    Publication date: June 24, 2010
    Applicant: EXELIXIS, INC.
    Inventors: Marcia Belvin, Helen Francis-Lang, Lori Friedman, Gregory D. Plowman, Timothy S. Heuer
  • METHODS AND APPARATUS RELATED TO MANAGEMENT OF EXPERIMENTS
    Publication number: 20100042351
    Abstract: In one embodiment, a method includes sending an indicator of an availability of a sample from a sample pool stored in a physical inventory. The sample being included in the sample pool based on an attribute of the sample satisfying a condition associated with the sample pool. An indicator that the sample has been selected from the sample pool for analysis at a first test site included in an array of test sites is received. A rule is retrieved from a rule database based on an experimental parameter value associated with the first test site. At least one of the experimental parameter value associated with the first test site or an experimental parameter value associated with a second test site is modified based on a condition within the rule being satisfied.
    Type: Application
    Filed: July 10, 2009
    Publication date: February 18, 2010
    Inventors: Todd M. Covey, Darwin A. Farrow, Barton J. Friedland, Helen Francis-Lang, Malcolm Francis-Lang, Justin W. Mccarthy, Norman B. Purvis, JR., Santosh K. Putta, David B. Rosen, David M. Soper, David C. Spellmeyer
  • Method for Determining the Status of an Individual
    Publication number: 20090291458
    Abstract: Methods of determining status of an individual based on the use of biological specimen and analysis of reference population of cells are described.
    Type: Application
    Filed: May 22, 2009
    Publication date: November 26, 2009
    Applicant: Nodality, Inc.
    Inventors: Aileen Cohen, Helen Francis-Lang, Malcolm Francis-Lang
  • METHODS OF DETERMINING THE HEALTH STATUS OF AN INDIVIDUAL
    Publication number: 20090269773
    Abstract: Methods of determining health status based on analysis of single cells in a sample or set of samples from an individual are described.
    Type: Application
    Filed: April 29, 2009
    Publication date: October 29, 2009
    Inventors: Wendy J. Fantl, Helen Francis-Lang, Alleen C. Cohen, Garry P. Nolan, Malcol Frncis-Lang
  • C20ORF23 as modifier of the IGFR pathway and methods of use
    Publication number: 20090202563
    Abstract: Human C20ORF23 genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of C20ORF23 are provided.
    Type: Application
    Filed: March 10, 2005
    Publication date: August 13, 2009
    Applicant: EXELIXIS, INC.
    Inventors: Lori Friedman, Helen Francis-Lang, Annette L. Parks, Kenneth James Shaw, Lynn Margaret Bjerke, Timothy S. Heuer
  • RORS as Modifiers of the p21 Pathway and Methods of Use
    Publication number: 20090149413
    Abstract: Human ROR genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of ROR are provided.
    Type: Application
    Filed: December 1, 2008
    Publication date: June 11, 2009
    Applicant: EXELIXIS INC.
    Inventors: Helen Francis-Lang, Lori Friedman, Thomas Kidd, Siobhan Roche, Haiguang Zhang